NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
NAOV(NASDAQ:NAOV) TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 291,204 shares of its common stock (or common stock equivalents), at an offering price of $7.01 per share of common stock (or per common stock equivalent) in a registered direct offering pri
NanoVibronix Announces Grant of New U.S. Patent Further Expanding ENvue Medical’s Intellectual Property Portfolio
NAOV(NASDAQ:NAOV) TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,409,105 B2, titled “Insertion Device Positioning Guidance System and Method” on September 9, 2025 to ENvue Medical Holdings LLC (formerly ENvue Medical Holdings, Corp.), a wholly-owned subsidiary of the Company (“ENvue” or “ENv
NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology
NAOV(NASDAQ:NAOV) TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,402,953 B2, titled “Insertion Device Positioning Guidance System and Method” on September 2, 2025 to ENvue Medical Holdings LLC (formerly ENvue Medical Holdings, Corp.), a wholly-owned subsidiary of the Company (“ENvue” or “ENv
NanoVibronix Announces Reverse Stock Split
NAOVTYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m. ET on Monday, August 11, 2025. The Company’s common stock will c
NanoVibronix's ENvue Secures Patent For Pediatric Feeding Tube Guidance System, Advancing Toward Regulatory Clearance
NAOVENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System
NAOVTYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division (“ENvue Medical” or “ENvue”), a new U.S. patent for its pediatric feeding tube guidance system. U.S. Patent No. 12,324,632, titled “Insertion Device Positioning Guidance System,” further strengthens ENvue Medical’s intellectual property portfolio and reflects the Comp
NanoVibronix Announces Immediate Retirement Of CEO Brian Murphy; Appoints Doron Besser As New CEO
NAOVNanoVibronix Confirmed That A Series Of Posts Made Earlier Today With Respect To A $26M Registered Direct Offering Of Common Stock Of The Company Priced At $0.45 Under Nasdaq Rules Was Falsely Issued; Co Has Not Priced And Is Not Consummating Any Register
NAOVNanoVibronix Says Major Louisiana Hospital Selects ENvue Navigation Platform To Support Adult Feeding Tube Procedures
NAOVReported Earlier: NanoVibronix Prices $10M Public Offering Of 400K Shares Of Series G Convertible Preferred Stock And Warrants To Purchase 4.9M Common Shares At $2.04 Each
NAOVNanoVibronix: UroShield Shows Reductions In CAUTIs, Catheter Blockages And Hospital Visits
NAOVNanoVibronix Regains Nasdaq Compliance
NAOVNanoVibronix Shares Resumed Trade
NAOVNanoVibronix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 251.7%
NAOVNanoVibronix Renews And expands Distribution Agreement With Dukehill Healthcare Pty Ltd In Australia
NAOVNanoVibronix (NAOV) Stock Is Skyrocketing: What's Going On?
NAOVNanoVibronix shares are trading higher by 42.8% to $3.15 during Monday's session. The company announced on Friday that it published its UroShield study, which showed positive data.
NanoVibronix UroShield Study Published; Shows 86% UTI Reduction, 70% Fewer Blockages, Promotes Adoption For Patients With Indwelling Urinary Catheters
NAOVTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
NAOVNanoVibronix Announces 1-for-11 Reverse Stock Split, Effective Mar. 14
NAOVNanoVibronix shares are trading higher after the company announced it will acquire ENvue Medical Holdings
NAOVNanoVibronix Acquires ENvue Medical Holdings, Corp.
NAOVNanoVibronix Presents UroShield Clinical Study At The University Of Michigan
NAOVNanoVibronix Q1 EPS $(0.23) Up From $(0.67) YoY, Sales $921.00K Up From $354.00K YoY
NAOVNanoVibronix Reports FDA 510(k) Submission For PainShield MD Plus
NAOV